IN THIS ISSUE

Richard Mark Kirkner
The estimates range from $13.5 trillion to $47.6 trillion. The variables include the generosity of the benefit and forecasts for reining in health care expenditures.
Thomas Reinke
But discontinuation rate is high, and Wall Street is unimpressed by sales of the new class of migraine medications.
Frieda Wiley
They can add competition and lower prices, but some see authorized generics as a ploy to fend off competition from true generics.
Joseph Burns
In 2020, eight companies in the National Drug Purchasing Coalition hope to change how PBMs do business.
Peter Wehrwein

A blueprint for high-volume, high-quality lung cancer screening that is detecting cancer earlier—and helping to save lives

Clinical Brief

Multiple Sclerosis: New Perspectives on the Patient Journey–2019 Update
Summary of an Actuarial Analysis and Report